Bayer gadolinium-based contrast agent (GBCA) - unnamed in summary
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Bayer gadolinium-based contrast agent (GBCA) - unnamed in summary, covering 2023-11-15 to 2023-11-15. Get the full timeline:
Most recent: Clinical Trial Update: Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions [Phase 2]